Search Immortality Topics:

Page 8,658«..1020..8,6578,6588,6598,660..8,6708,680..»


International Stem Cell Corporation Not Adversely Affected by Stem Cell Research Funding Ban

Posted: October 11, 2010 at 10:12 am

OCEANSIDE, CA – August 26, 2010 – International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that the recent action of a federal district judge blocking federal funding of embryonic stem cell research is not expected to have negative effects on ISCO’s therapeutic programs using its human parthenogenetic stem cells.

According to ISCO’s Chairman Ken Aldrich, “Because we have never depended on federal or state money to fund our research, the new ruling is simply not applicable to any of our programs in the US or any of our international efforts. Although we believe anything that restricts legitimate scientific research is detrimental to science and our Country and hope the ruling is quickly reversed, the ruling could in a strange way benefit ISCO by creating additional incentives for researchers to use our parthenogenetic stem cell lines.”

Because ISCO’s technology, parthenogenesis, does not destroy or damage a viable human embryo, its parthenogenetic stem cell lines (“hpSC”) offer an alternative way to continue research previously done with embryonic cell lines without raising ethical issues about the destruction of life. Published peer-reviewed papers have shown hpSC to be “pluripotent”, a characteristic shared with embryonic stem cells that allows them to become tissues leading to all the cells found in the human body. Therefore, ISCO’s hpSC lines offer an alternative to the ethical issues that continue to be problematic for embryonic stem cells.

When enacted, legislation prohibiting the creation of a human embryo for research purposes prohibited both successful methods, such as fertilization, as well as less understood methods such as parthenogenesis. Parthenogenetic methods since developed by ISCO do not create human embryos that could become viable human beings, yet can result in pluripotent hpSC lines with potential therapeutic value. “The recent court ruling may cause Congress to revisit its legislation. If so, then ISCO’s research showing its hpSC lines present an alternative to embryonic stem cells, without raising the ethical concerns about the creation or destruction of viable human life, may lead to Congress allowing federal funding of hpSC in future legislation. ISCO would then be free to provide hpSC lines to federally-funded researchers and move more of our work back into the US from foreign jurisdictions”, said Jeffrey Janus, Senior Vice President of ISCO and one of its founders.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike all other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals across racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, develops a line of cosmeceutical products via its subsidiary Lifeline Skin Care and advances novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics do not. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

CONTACTS:
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Jeffrey Janus
Sr. Vice President, Operations
760-640-6383
jjanus@intlstemcell.com

Recommendation and review posted by G. Smith

International Stem cell Corporation Chairman Discusses Recent Stem Cell Research Funding Decision

Posted: October 11, 2010 at 10:12 am

This is Ken Aldrich and I am Chairman of International Stem Cell Corporation and I thought I should comment briefly on the recent decision of the federal district court of the District of Columbia concerning stem cell research.

What the court did was to announce that it was prohibiting the use of federal funding by the NIH for embryonic stem cell research which is a major blow if the decision is upheld for the stem cell industry. It’s interesting because it actually does not affect International Stem Cell Corporation in any direct negative manner.

The truth of the matter is we have not been able to use federal funding since the very beginning of the company because of a particular provision in the Dickey Wicker amendment that specifically calls out parthenogenic stem cells as a form of embryo, in spite of the fact that they genuinely are not an embryo in fact cannot ever become any living human being and don’t involve the destruction of anything that could become human being. Nevertheless, we have always been caught up in the Dickey Wicker amendment. So we haven’t been hurt by this decision, if anything it has perhaps leveled the playing field for us a bit with the embryonic stem cell group.

But the bottom line is we don’t really think it is good for the country and we hope there will be a change. But we do hope is that perhaps this will open the political debate and as people begin to look at the broader spectrum and realize that parthenogenic stem cell, which is our stock and trade, do not involve the destruction of any embryos, it may be that the specific language of the Dickey Wicker amendment can ultimately be removed and we would then become eligible along with everyone else for federal funding through the NIH and other government programs. If so, it would be a wonderful result. In the meantime, it is a difficult time for everyone in the industry. We’ll keep you informed. Thank you

Recommendation and review posted by G. Smith

International Stem Cell Corporation Formalizes Stem Cell Based Eye Care Programs into Cytovis™

Posted: October 11, 2010 at 10:12 am

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™. Together these programs will leverage external and internal development, regulatory and commercial expertise in cellular ophthalmology to form a focused portfolio of complementary product candidates designed to address high unmet medical needs with apparent pharmacoeconomic and quality of life benefits.


CytoCor is the brand name for ISCO's corneal tissue that can be derived from the company's proprietary parthenogenetic stem cells or commonly used embryonic stem cells. Research and development with partners Absorption Systems in the US,Sankara Nethralaya in India and Automation Partnership in the UK continues for the purpose of optimizing the tissue for transplantation in the 10 million people worldwide suffering from corneal vision impairment and as an alternative to the use of live animals and animal eyes in the $500+M market for safety testing of drugs, chemicals and consumer products. ISCO's goal in the coming months is to establish funding and infrastructure in India for accelerated development of CytoCor for the therapeutic application and to advance and implement the chemical testing application with partners in the US and Europe.


CytoRet is the brand name for ISCO's stem cell-derived retinal tissue. ISCO is using its parthenogenetic stem cells to develop individual retinal pigmented epithelial ('RPE') cells and layered retinal structures internally and in collaboration with the laboratory of Dr. Hans Keirstead, Professor of Anatomy and Neurobiology at the University of California, Irvine. ISCO recently commenced a new research collaboration with UC Irvine to launch the next phase of its retinal studies with that institution, including preclinical trials. Potential therapeutic applications include retinitis pigmentosa, an untreatable inherited disease affecting about 100,000 Americans, and the dry form of age-related macular degeneration, a major cause of blindness in the elderly of the Western world. ISCO's goal is to establish functional proof of concept for RPE cellular therapy in models of human disease in the next twelve-eighteen months.


Jointly referred to as Cytovis ('cyto' for cellular, 'vis' for vision), these two cellular ophthalmology programs share a number of features and benefits. First, with the aging of the population worldwide and the growing number of work-related eye injuriesin India, China and other major countries, the market opportunity is growing steadily. Second, there are strong pharmacoeconomic and quality-of-life rationales for full or partial vision restoration or delay of vision impairment diseases. Third, delivery of cells and tissues to the confined anatomy of the eye inherently provides for better safety and efficacy than, for example, the systemic circulation or the central nervous system. This will likely result in lower regulatory barriers and shorter and less costly development paths compared to that of anatomically deeper and more widespread diseases. Fourth, a number of eye diseases cannot be treated with surgery or traditional small molecule or protein therapeutics, yet cell and tissue therapy is proven to work but currently limited by availability of safe and sufficient cells and tissue from human donors. Finally, eye care development programs like CytoCor and CytoRet share a number of regulatory, development and commercial aspects that make it feasible for a relatively small team to produce substantial clinical outcomes and achieve competitive presence in the marketplace alone or in collaboration with dedicated partners.


Brian Lundstrom, ISCO's President, says: 'ISCO's proprietary parthenogenetic stem cell technology continues to form the foundation for the company's long term regenerative medicine therapy programs. In the nearer term, CytoCor and CytoRet's unique benefits in the field of cellular ophthalmology offer the potential for partnering and funding at a relatively early stage. Combined with the current and future revenue of Lifeline Cell Technology and the revenue potential of Lifeline Skin Care, scheduled for launch in the 4th quarter, Cytovis adds significantly to ISCO's diversity and value creation potential for its investor base in a cost-efficient fashion.'


ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike all other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals across racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, develops a line of cosmeceutical products via its subsidiary Lifeline Skin Care and advances novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics do not. More information is available at ISCO's website, http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.


Key Words: Stem Cells, Biotechnology, Parthenogenesis


International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

Recommendation and review posted by G. Smith

REPRINT of Old Post from Cold Filter Cryonics Forum

Posted: October 11, 2010 at 10:12 am

In searching for some information for a new post I wanted to make, I stumbled upon an exchange I had with Ben Best, about Suspended Animation, more than two years ago. I wanted to preserve it on my blog, and find it still relevant since SA continues on a path of incompetence, (see this recent post, and this), so here it is:

Endless Debate
April 18 2008 at 6:14 PM


Ben: If SA had failed to wash-out the blood, then that could be a source of blood on the board, even without vascular damage. So it is contradictory to claim that the only source of blood could have been from vascular damage when you are claiming that residual blood would be expected from an inadequate wash-out.


You are correct, in that I should have written "possible evidence," as the blood Andy described could have indicated several things. I believe SA over-pressurized the patient to the point of vascular damage, due to what I consider to be a mountain of evidence in the SA report, regarding alarms, the funeral director inquiring if the pump was on at the time of the spurt, etc., and the general inability of the team to address the pressure issues they were obviously experiencing, as well as my personal knowledge of the members of the team and their capabilities (or lack thereof), and my expertise in perfusion. I believe the patient was subsequently under-perfused, due to what I calculate to be a rather low average flow rate.

Ben: In any case -- as I pointed-out previously -- a clot associated with the stroke hemorrhage in the right hemisphere dislodged during the vitrification perfusion, and there was adequate release of blood to explain blood on the board.

Andy has already anticipated the question I was going to ask, here, and has stated that perfusion was continued, following the removal of the clot, until the effluent was clear, and that the board was subsequently clean. SA attempted to perfuse the entire patient (both head and body), and CI perfused the head a second time, but it seems that blood remained in the patient and drained later, indicating an incomplete washout. I have to agree with Andy, that it is more probable the blood came from the body, rather than the head that was perfused twice, and I can’t imagine you want to argue that CI didn’t do an adequate isolated perfusion of the head.

Why did the clot remain, following SA’s attempts to perform the washout procedure, anyway? What about the clot-dissolving medications (streptokinase) the SA team supposedly administered? Are you aware that streptokinase is contraindicated in stroke patients? "Streptokinase has not been shown to benefit patients with acute ischemic stroke, but it has been shown to increase their risk of intracranial hemorrhage and death. Of 3 major randomized controlled trials, all were terminated prematurely because streptokinase was associated with unacceptable rates of mortality." http://www.emedicine.com/EMERG/topic558.htm

Ben: My use of the word "fabrication" was meant in the sense of rationalization not intentional deception ("lie"). I believe the authors wrote that the blood spurt occurred under pressure from the ATP to rationalize or explain the spurt, without good evidence for this rationalization.

Where I come from, (the South), the word "fabrication" is a polite word for "lie." At any rate, there should be no tolerance of "rationalization," or "fabrication," in a medical case report. Of course, what can we expect from someone who excels at writing FICTION? (Not that there is anything wrong with fiction, when it is identified as such.) There’s a lot of other information that should not have been included in the SA case report, such as comments about an employee’s second job, and comments about a former employee, and I think you know the spirit in which those comments were made. I believe there has been a lot of "rationalization" at SA, in the past, "rationalization" that has perhaps led to quite a few ill-advised courses of action, the firing and resignations of capable persons, AND perhaps in people like you, Ben, believing in the capabilities of SA more than you should.

Ben: There would be no motive for the authors to intentionally deceive readers into believing that the ATP caused the blood spurt. That is the crux of your case that damage was caused.

You've hit the proverbial nail on the head, Ben. The authors could not possibly want to deceive people into believing they over-pressurized the patient. The point is: THEY DID NOT KNOW ENOUGH ABOUT PERFUSION TO REALIZE THE IMPLICATIONS OF WHAT THEY WERE WRITING!! The crux of my case that damage was caused are details in the report, and the fact that the SA team and case authors didn't have a clue as to what they were doing, or even writing. I think it's blatantly obvious they were too ignorant of perfusion technology to realize that what you now call a "rationalization" would strongly indicate damaging over-pressurization of the patient. Who in the world would create, and include, fabricated remarks in a report, that would indicate malpractice??? Only someone who was not knowledgeable enough to understand that what he was writing would indicate gross mistreatment of a patient. Why are you so willing to turn over the care of CI's patients to people who know so little about the medical procedures they claim to be capable of providing? How can you call them “experts,” and refer to their services as “state of the art,” when their staff members are extremely unqualified and they are decades behind, in regard to the quality of care provided in conventional medicine, in virtually identical procedures?

Ben: I could say that your arguments are self-serving because you have had bitter personal experiences with Charles Platt and you want to prove that he is an evil, incompetent man. It is better to stick to the evidence of the case than to challenge motives and character -- which too easily leads to acrimony.

I don't think I would call Charles, (or anyone), "evil," and I don't think he is "incompetent," in general. (I think you'll find me sincerely praising his writing skills, and other talents, on this forum, on a number of occasions.) However, I do believe he has no place in managing people, or in making decisions regarding medical procedures and/or the related equipment.

Are the motives and character of someone who exerts a significant amount of influence over major decisions of a company that is offering medical services irrelevant? I think not. What if their motives ARE self-interest, greed, or their own egotistical needs, more so than patient care or overall progress in the field?

If you consider someone who doesn't want cryopreservation to be “committing suicide,” as you seem to, then is a company providing less than optimal medical care, when they can afford quality professionals and equipment, not guilty of “negligent homicide,” at best? Why should a company send a fabricator to attempt a very dangerous medical procedure, when they pay him the same salary as a qualified person who could SAFELY perform the procedure? I have no idea how you can be supportive of this behavior, or how you don't see that the main focus of SA, for many years, has been certain "engineering" projects, rather than the provision of competent patient care. I believe this is clearly evidenced by the three inexperienced, unqualified people who showed up for the CI-81 case.

Ben: I think that what serves me best is to know the truth, whether this be mistakes or a job well done. The case reports I write disclose many mistakes, including mistakes made by me. The best way to avoid repeating future mistakes is to document them well and think about how to avoid making the same mistakes again in the future.

The best way for SA to avoid mistakes in perfusing a patient, would be to take the $77,000 being paid to one of the fabricators who was on the CI-81 team and pay it to a perfusionist. They can report perfusion mistakes until the earth gets swallowed up by the sun, but they are not going to be able to properly train laymen with a weekend trip to California, some videos, and one case in four years. Anyone who thinks they can doesn't have a proper understanding of perfusion technology.

Ben: I do not accept the claim that if a person perfusing a cryonics Patient has not had four years of perfusion training that that the patient will necessarily have experienced vascular damage

I certainly agree that I could have probably been a good perfusionist without the numerous hours of English, History, Government, Psychology, and other classes I was required to take for my degree, but I believe I would have killed quite a number of patients without my clinical experience. I performed 110 cases, on human patients, with an instructor standing over my shoulder, to prevent me from harming anyone, before I graduated perfusion school. This was after many months of classroom instruction on perfusion techniques, and with a good understanding of anatomy and physiology. How in the world can anyone as intelligent as you, believe Gary and Ken can walk out of the shop and safely perform perfusion? You can only think this because, as my husband says, "people don't know what they don't know." What you don't know about perfusion and the SA personnel allows you to believe they can safely perform whole body perfusion, but I believe I know better.

Ben: By that logic every cryonics patient ever perfused or given a wash-out by CI or Alcor would have experienced serious vascular damage -- more harm than good -- because they were not perfused or washed-out by a professional perfusionist. Why single-out the 81st patient?

It's wrong of you to say I assume every patient has experienced serious vascular damage, as there isn't much evidence of over-pressurization in CI's reports. The circuit pressures CI mistakenly recorded as patient pressures would have been significantly higher than the actual patient pressures, so I doubt any pressure-induced vascular damage occurred. In that situation, I would be more concerned with wondering if the pressure was high enough to adequately perfuse the brain. I single out the 81st patient because it's the only SA case report I've thoroughly reviewed, and as far as I know it is the only case performed by the current staff. As I’ve mentioned, many times before, my purpose is to expose what I believe to be irresponsible and unethical behavior at a company of which I have firsthand knowledge, so I have no idea why you think I would discuss Alcor, or CI cases, in which SA was not involved. There are a number of other reasons I single out the SA case, including the fact that SA can afford medical professionals, while Alcor and CI may not be able to.

Ben: I acknowledge that improving perfusion quality is important, and I believe that Alcor, CI and SA are all making efforts to improve perfusion quality. The point at issue here is not whether perfusion in cryonics (or for the 81st patient) could have been better, but whether vascular damage was caused.

The REAL question I’m asking is: Why is SA not providing qualified, experienced perfusionists and EMTs or paramedics, when they can easily afford to? Why should they pay equivalent salaries to people who don't even understand the procedures enough to realize what their reports indicate, or worse yet, to people incapable of even authoring their own reports, due to their total lack of knowledge in regard to the procedures, and medicine and cryonics, in general?! With the salaries they pay, SA should be providing EXCELLENT, PROFESSIONAL medical services, not simply "better" than what has been available in cryonics, in the past.

I respectfully, but strongly, disagree with your comments in regard to SA's efforts to improve. I don't see any evidence of change, other than the last News Bulletin which indicated they have implemented a few suggestions Mathew, Aschwin and I made a long time ago, suggestions that were previously ignored, (BLS certification, lift gates, etc.) It also included news regarding the new "workshop" in California, which only leads me to believe the primary focus of SA remains the "engineering and design" projects of Charles Platt. We haven't heard anything from SA, in months. When you tell me SA is using the more than half-a-million-dollars I (conservatively) estimate they are spending, annually, on their payroll and consulting fees, to pay for medical professionals, as they should, I'll believe SA is making an effort to improve.

Ben: Even if a single spurt caused some harm (and this is questionable if a spurt would relieve pressure and the ATP was immediately turned-off) it does not constitute evidence that it resulted in such damage as to override the many benefits of the SA treatment for the patient.

WHAT BENEFITS, Ben??? Packing the patient in ice and performing chest compressions, or injecting meds into IVs that were, fortunately, left in place by hospital personnel? (I don't believe any of the three SA team members would have been able to gain IV access.) Almost anyone off the street could and would do those things, for not much more than minimum wage, so why does SA WASTE a payroll and consulting fees that are most certainly well over a half-a-million dollars a year on this??? (Again, I think this figure is conservative.) Don't you get my point that SA could have a qualified perfusionist, and medical personnel experienced at intubation and the insertion of IVs, for the amount of money they spend on employees and consultants?? And, why do you believe CI's clients should pay $60,000, (about three times the cost of open-heart surgery), for a bunch of rank amateurs to possibly harm them through the improper use of a perfusion circuit, rather than leaving that money to cryonics research, or their heirs? Note from October 10, 2010: I neglected to note that this comment, from Ben, was inherently ridiculous. it was not the "single spurt" that would have caused the harm, but the pressure that had built up inside the patient, prior to the incision, (which resulted in the spurt), that would have been deleterious. The spurt was not the problem; it was evidence that inappropriate pressures had been applied to CI-81's vascular system, and hence all internal organs and tissues, (including the brain, of course), for god-knows-how-long, prior to the cannulation attempt.

Ben: I am not claiming to certain knowledge of what happened during the wash-out. Any scenario I can construct of the events associated with the blood spurt is like a jigsaw puzzle with a few pieces missing -- or pieces that don't fit. But although all the explanations have deficiencies, none of them can be used to make a convincing argument for vascular damage. This was the key point of my posting, and you did not address this point in your reply.

I think the report has more than enough circumstantial evidence that charges of gross negligence and malpractice, most likely including over-pressurization to the point of vascular damage, would hold up in court, if this were not a "legally dead" person.

Ben: I regret if anything I have had to say here strikes you as a personal offense.

Ditto. I also regret that we have such strong difference of opinion, in regard to the services of SA, but you know I will argue that I understand perfusion better than you, and that I have experience working with the SA staff and consultants, other than Ms. Baldwin. You don't offend me, but you disappoint me by continuing to endorse a company I feel has behaved unethically, and has shown little evidence of a change in strategy.

CI is, for the most part, SA’s only source of new clients and therefore holds the leverage to force that company to behave more responsibly by demanding they provide experienced, qualified personnel, (which would not affect their budget), yet you don’t do this. In my mind, there won't be significant change at SA, for as long as the staff and consultants remain the same, and you are helping to maintain the status quo. Unfortunately, I feel this endless debate could go back-and-forth, forever, so I think we are just going to have to agree to disagree.

Recommendation and review posted by G. Smith

Impersonating a Physician

Posted: October 11, 2010 at 10:12 am

From Healthgrades.com:

"WARNING: Federal Law prohibits any person from:

•Impersonating a physician
•Falsely representing themselves as a physician
•Falsely claiming to represent a physician
•Falsifying physician information or
•Any other fraudulent activities related to physician identification and/or information"
http://www.healthgrades.com/profile-manager/Security/PrimaryLandingPage.aspx?ReturnUrl=%2Fprofile-manager%2FDefault.aspx

I don't know about everyone else, but I believe referring to one's self, as a "surgeon," (ala Catherine Baldwin and others working in cryonics), is the same as "impersonating a physician," or "falsely representing themselves as a physician," since one cannot be a surgeon without first being a physician. (ALL surgeons are physicians, hence calling one's self a "surgeon" is equivalent to calling one's self a "physician.")

In addition to federal laws, there are state laws against mispresenting one's self as a physician.

Recommendation and review posted by G. Smith

More Cryonics Forum Foolishness

Posted: October 11, 2010 at 10:12 am

In response to my pondering whether it is legal for Alcor to refer to the residents of the Dewars as "patients," some anonymous soul, on CF responded:

"The U.S. Constitution says:

"Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; _or abridging the freedom of speech, or of the press_"

Of course it is legal for Alcor to say whatever they like. If you don't like it, it is also legal for you to disagree, using your own printing press, as you are doing."
http://www.network54.com/Forum/291677/message/1286384136/Is+it+legal+to+say+that-

First Amendment protection does not allow individuals, or entitites, to "say whatever they like," and if "Fundie" wants proof of that, he should consult with Charles Platt, or maybe with Mr. Platt's attorney, who specializes in law related to First Amendment protection.

In addition to the obvious restriction of laws related to libel and slander, there are also laws that prohibit people from impersonating physicians and other medical professionals. In calling their clients "patients," I believe organizations such as Alcor and Suspended Animation are implying the existence of qualified medical personnel. In addition to that, they often refer to their personnel as "surgeons," or other medical professionals, when the people they are referring to often have absolutely no medical training, and are not physicians, much less surgeons. This seems to be a fraudulent public representation of their personnel, and I think it should be against the law...if it's not, already.

Recommendation and review posted by G. Smith


Page 8,658«..1020..8,6578,6588,6598,660..8,6708,680..»